{"id":"hf10-plus-ipilimumab","safety":{"commonSideEffects":[{"rate":"null","effect":"Diarrhea"},{"rate":"null","effect":"Colitis"},{"rate":"null","effect":"Hypophysitis"},{"rate":"null","effect":"Adrenal insufficiency"},{"rate":"null","effect":"Nephritis"}]},"_chembl":{"chemblId":"CHEMBL1789844","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The HSP90 inhibitor, HF10, targets and inhibits the heat shock protein 90, which is involved in the folding and stabilization of various proteins, including those involved in cancer cell growth and survival. The CTLA-4 inhibitor, Ipilimumab, blocks the activity of cytotoxic T-lymphocyte-associated protein 4, a protein that downregulates the immune response, thereby enhancing the immune response against cancer cells.","oneSentence":"HF10 plus Ipilimumab is a combination of a heat shock protein 90 (HSP90) inhibitor and a CTLA-4 inhibitor, which works by blocking the activity of heat shock protein 90 and cytotoxic T-lymphocyte-associated protein 4, respectively, to enhance the immune response against cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:34:06.702Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Unresectable or metastatic melanoma"}]},"trialDetails":[{"nctId":"NCT03153085","phase":"PHASE2","title":"A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma","status":"COMPLETED","sponsor":"Takara Bio Inc.","startDate":"2017-05-25","conditions":"Melanoma Stage III, Melanoma Stage IV","enrollment":28},{"nctId":"NCT02272855","phase":"PHASE2","title":"A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma","status":"COMPLETED","sponsor":"Takara Bio Inc.","startDate":"2014-04-30","conditions":"Malignant Melanoma","enrollment":46}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["YERVOY (for ipilimumab)"],"phase":"phase_2","status":"active","brandName":"HF10 plus Ipilimumab","genericName":"HF10 plus Ipilimumab","companyName":"Takara Bio Inc.","companyId":"takara-bio-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"HF10 plus Ipilimumab is a combination of a heat shock protein 90 (HSP90) inhibitor and a CTLA-4 inhibitor, which works by blocking the activity of heat shock protein 90 and cytotoxic T-lymphocyte-associated protein 4, respectively, to enhance the immune response against cancer cells. Used for Unresectable or metastatic melanoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}